ReviewInternational journal of molecular sciences2021
Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 48 citations in OpenAlex.
- New perspectives in the treatment of chronic eosinophilic pneumonia in the era of targeted therapies.Frontiers in immunology · 2026Review
- Blood eosinophils as predictors of asthma exacerbations in adults: converging evidence from mendelian randomization, single-cell transcriptomics, and a two-center longitudinal cohort.Frontiers in immunology · 2026Article
- Screening and Preliminary Validation of Parthanatos-Related Key Genes in Asthma Using Transcriptomic and Machine Learning Approaches.Journal of inflammation research · 2026Article
- Review
- Diagnostic value of EOS count and serum VEGF in bronchial asthma and their correlation with inflammatory factors and lung function indicators.BMC pulmonary medicine · 2025Article
- Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.International journal of molecular sciences · 2025Review
- Optimizing diagnostic and management pathways for patients with eosinophilia of unknown origin: a multidisciplinary protocol for urgent and non-urgent evaluation.Frontiers in medicine · 2025Article
- Comparison of pharmacokinetic similarity, immunogenicity, and safety of mepolizumab and BAT2606 in healthy Chinese men in a double-blinded, randomized, single-dose, three-arm parallel-group phase I trial.Frontiers in pharmacology · 2025Article
- Phenotypic Shift of an Inflammatory Eosinophil Subset into a Steady-State Resident Phenotype after 2 Years of Vaccination against IL-5 in Equine Insect Bite Hypersensitivity.Veterinary sciences · 2024Article
- Exploring the therapeutic potential of monoclonal antibodies targeting TSLP and IgE in asthma management.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
- Genetic Evidence for a Causal Relationship Between Innate Leukocytes and the Risk of Digestive System Cancers in East Asians and Europeans.World journal of oncology · 2024Article
- Equine Asthma Does Not Affect Circulating Myostatin Concentrations in Horses.Animals : an open access journal from MDPI · 2024Article
- Radiation-Detoxified Form of Endotoxin Effectively Activates ThInternational journal of molecular sciences · 2024Article
- Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis.Journal of clinical medicine · 2023Review
- Eosinophilic Airway Diseases: From Pathophysiological Mechanisms to Clinical Practice.International journal of molecular sciences · 2023Review
- The Anti-Inflammatory PeptideCells · 2023Article
- Subsets of Eosinophils in Asthma, a Challenge for Precise Treatment.International journal of molecular sciences · 2023Review
- High density lipoprotein-cholesterol is inversely associated with blood eosinophil counts among asthmatic adults in the USA: NHANES 2011-2018.Frontiers in immunology · 2023Article
- Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma.Respiratory research · 2022Article
- Baseline Eosinophil Count as a Potential Clinical Biomarker for Clinical Complexity in EGPA: A Real-Life Experience.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Asthma is now recognized as a heterogeneous disease, encompassing different phenotypes driven by distinct pathophysiological mechanisms called endotypes. Common phenotypes of asthma, referred to as eosinophilic asthma, are characterized by the presence of eosinophilia. Eosinophils are usually considered invariant, terminally differentiated effector cells and have become a primary therapeutic target in severe eosinophilic asthma (SEA) and other eosinophil-associated diseases (EADs). Biological treatments that target eosinophils reveal an unexpectedly complex role of eosinophils in asthma, including in SEA, suggesting that "not all eosinophils are equal". In this review, we address our current understanding of the role of eosinophils in asthma with regard to asthma phenotypes and endotypes. We further address the possibility that different SEA phenotypes may involve differences in eosinophil biology. We discuss how these differences could arise through eosinophil "endotyping", viz. adaptations of eosinophil function imprinted during their development, or through tissue-induced plasticity, viz. local adaptations of eosinophil function through interaction with their lung tissue niches. In doing so, we also discuss opportunities, technical challenges, and open questions that, if addressed, might provide considerable benefits in guiding the choice of the most efficient precision therapies of SEA and, by extension, other EADs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.